The Eurobioforum 2013 conference discussed strategies for managing disease and treatment complexities while promoting R&D innovations in healthcare. Key initiatives include the establishment of the Center for Medical Innovation (CMI) to streamline clinical applications and the Nanotechnology for Health project in Flanders, which aims to integrate academic research with industry needs. Collaborative efforts across borders and sectors are emphasized to foster advancements in health-related technologies and accelerate market introduction.

1. 27-­‐28
May
2013,
Munich,
Germany
EuroBioForum
2013
2nd
Annual
Conference
Wolfgang
Eberle
imec

3. Solu>ons
in
a
sea
of
technologies
…
a
solu>on?

4. IP
…
R&D
effort
…
cost
…
quality
control
…
risk
management
…
tes>ng
…
approval
…
system
architecture
…
return-­‐of-­‐
investment
…
lifecycle
…
>me-­‐to-­‐market
…
robustness
…
purpose
…
market?

5. • develop
suitable
technologies
to
manage
– disease
complexity
– treatment
complexity
– cost
efficiency
• ways
to
involve
all
stakeholders
– mul>ply
excellence
by
interac>on
between
different
clusters
– Increase
the
chance
to
bring
R&D
innova>on
to
each
of
us
– incen>ves
to
keep
R&D
innova>on
ongoing
• methods
&
policies
suppor>ng
longer
term
strategies
– new
structured
alliances
– gap
funding
WHAT
ARE
WE
LOOKING
FOR?

6. FLANDERS: Key Figures and competencies
pop : 6 3 million ( 58 % f BE)pop.: 6.3 million (= 58 % of BE)
GDP: €202.6 billion (2010)
GDP / capita: €32,300 (2010)
companies: 462,661 (2011)
R&D personnel: 38,216 FTE (2010)
% GERD / BBP: 2 15% (2011)% GERD / BBP: 2.15% (2011)
Innovating companies : 53% of total (CIS)
FP7: VL return: 2.43%; or € 539.1 million (Oct 2011)
G € ( / f )GERD: €4.33 billion (2/3 of BE) (2010) , of which:
€ 2.82 billion BERD;
VLA public STI outlays: €1,891 million, (of which €1.20 billion R&D) ;p y ( )
Fed. public R&D outlays: €238 million;
EU STI funding: +- €120 m (€103 m FP7; €8 m ERDF ; €7 m Interreg);
exclusive powers on higher education, scientific research, innovation
(= all broad R&D & I (in)direct support, all research related to own regional &
community competencies, universities, university colleges, access to finance,
Flemish government | Department of Economy, Science and Innovation
4
y p , , y g , ,
various knowledge institutes, PROs, scientific institutes, science parks).
Flanders
|
Belgium
|
Europe
FLANDERS: Key Figures and competencies
pop : 6 3 million ( 58 % f BE)pop.: 6.3 million (= 58 % of BE)
GDP: €202.6 billion (2010)
GDP / capita: €32,300 (2010)
companies: 462,661 (2011)
R&D personnel: 38,216 FTE (2010)
% GERD / BBP: 2 15% (2011)% GERD / BBP: 2.15% (2011)
Innovating companies : 53% of total (CIS)
FP7: VL return: 2.43%; or € 539.1 million (Oct 2011)
G € ( / f )GERD: €4.33 billion (2/3 of BE) (2010) , of which:
€ 2.82 billion BERD;
VLA public STI outlays: €1,891 million, (of which €1.20 billion R&D) ;p y ( )
Fed. public R&D outlays: €238 million;
EU STI funding: +- €120 m (€103 m FP7; €8 m ERDF ; €7 m Interreg);
exclusive powers on higher education, scientific research, innovation
(= all broad R&D & I (in)direct support, all research related to own regional &
community competencies, universities, university colleges, access to finance,
Flemish government | Department of Economy, Science and Innovation
4
y p , , y g , ,
various knowledge institutes, PROs, scientific institutes, science parks).

7. Innova>on
framework
Neuro-electronics research -
flanders (NERF)
3
K.U.Leuven &
University Hospital
VIB
Biotechnology
imec
Nanoelectronics
+ 1000 m2 NERF bio-lab @ imec
~ 1950 researchers
~ 260 PhDs
~ 350 industrial residents
~ 300 MEuro R&D
~ 18000 researchers &
staff (>2000 beds;
doubling in the next years)
~ 570 PhDs
~ 330 MEuro R&D
~ 1250 researchers
~ 180 PhDs
~ 90 MEuro R&D

9. Co-­‐locate
for
efficient
life
science
technology
R&D

10. Neuro-electronics research -
flanders (NERF)
3
K.U.Leuven &
University Hospital
VIB
Biotechnology
imec
Nanoelectronics
+ 1000 m2 NERF bio-lab @ imec
~ 1950 researchers
~ 260 PhDs
~ 350 industrial residents
~ 300 MEuro R&D
~ 18000 researchers &
staff (>2000 beds;
doubling in the next years)
~ 570 PhDs
~ 330 MEuro R&D
~ 1250 researchers
~ 180 PhDs
~ 90 MEuro R&D
Cross-­‐fer>lize
applied
technology
&
basic
research

11. 7
Cross-border collaboration: Body Area Network activities in Nl.
Join
forces
across
borders
for
a
larger
R&D
market

12. Accelerate
the
tech-­‐to-­‐clinical
trial
route
23/05/13 14:50Center for Medical Innovation
The CMI has been created as a non-profit foundation by the Government of Flanders in collaboration
with the universities/university hospitals and the health care industry in Flanders to accelerate the
translation of innovation in human health care into novel clinical applications. CMI’s first project is the
creation and coordination of the Flemish Biobank, a virtual biobank in specific disease fields, according
to strict quality criteria for biomaterials and accompanying clinical data sets.
The CMI activities contribute in a major way to:
Accelerated access to know-how as well as health care products and strategies for the end-user:
patient and physician.
Better understanding of diseases, their evolution, their treatment and their prevention.
The creation of technology platforms that allow for the genesis of new companies with focus on
health care and med-tech.
Smooth transition from academic know-how and understanding to innovation into the R&D
process that turns ideas into applications and products.
Get to know the CMI !
CMI is a member of
Welcome News History Management Contact Members Only
The CMI has been created as a non-profit foundation by the Government of Flanders in collaboration
with the universities/university hospitals and the health care industry in Flanders to accelerate the
translation of innovation in human health care into novel clinical applications. CMI’s first project is the
creation and coordination of the Flemish Biobank, a virtual biobank in specific disease fields, according
to strict quality criteria for biomaterials and accompanying clinical data sets.
The CMI activities contribute in a major way to:
Accelerated access to know-how as well as health care products and strategies for the end-user:
patient and physician.
Better understanding of diseases, their evolution, their treatment and their prevention.
The creation of technology platforms that allow for the genesis of new companies with focus on
Welcome News History Management Contact Members Only
CMI
–
Center
for
Medical
Innova>on

13. Fund
beyond
novelty
-­‐
Fund
the
gaps
• Feasibility
&
innova>on
grants
for
SME
• Grants
for
new
markets
&
products
• Applied
biomedical
research
(TBM)
• Transforma>onal
medical
research
(TGO)
• Feasibility
&
innova>on
grants
for
SME

14. 2
Short description of the case & Key-Players:
• Nanotechnology for Health (NfH): an emerging and promising field;
• Mature players looking for further differentiationadopting nanotechnology
allowing to interact at a sub-cellular level and start-ups, especially active as nanotechnology
providers.
• A strong installed basis in the area of bio-pharma and biotech companies (>300 companies in B)
• Flanders has a 3 strong major complementary pillars (knowledge base):
- Imec (among the largest nano-electronics independent R&D centers world wide diversifying
into nano-electronics for health
- University Hospital Leuven being the largest clinical setting in Europe
- VIB: a internationallyrecognized large instituteof biotechnology
• NfH case focusing on cluster approach & strategic alliances,both in Flanders and
cross-border!
Explore
capability
&
capacity
5
Eco-system for NfH & innovation chain integration
Academia &
Research Centers
Industry
• Selection of Flemish
Universities & R&D centers
•Selection of Dutch
universities
• e.g. Promising case of
Biocartis (diagnostics)
- Most innovative company of 2011 in
medical segment by World Economic
Forum 2011
- Raised 71 MEuro in current climate
Bringing together top-excellence
In nanotech related health
Focus
Strengthening position by
adopting nanotechnologies &
creating interacting eco-system
of nanotech providers & adopters
Cross-border smart specialist region
Focus
on
cluster
approach
&
strategic
alliances,
both
in
Flanders
and
cross-­‐border
Nano
for
Health
-­‐
NfH
-­‐

15. Health Axis Europe
Matching Cluster Profiles
6
Cambridge Leuven Heidelberg
Internationally outstanding universities with
excellent health sciences and a
strong tradition in top education and research
Substantial health industry base
Driven by strong key individuals
who are personally committed to foster
economic growth and entrepreneurship
Focused on complementary health technology areas
Regenerative medicine
and stem cells
Medical electronics
and nanotechnology
Personalized medicine
and cancer research
Upscale
the
impact
KIC
HEALTH

16. 2002:
spin-­‐off
VIB+VUB,
2MEuro
seed
2013:
31MEuro
capital
raise
2006:
spin-­‐off
Ugent+IMEC
Bring
to
market
through
several
routes

17. • create
&
enable
top
players
in
their
respec>ve
field
• focus
• re-­‐invest
for
strategic
steps
• create
interac>on
opportuni>es
across
stakeholders
• build
structural
alliances
for
las>ng
impact
• co-­‐develop
an
eco-­‐system
with
industry
• facilitate
abundant
interac>on
opportuni>es
• ensure
KPIs
along
the
innova>on
chain
Achieving
tangible
results

18. Thank
you
imec
Contact:
Dr.
Wolfgang
Eberle
Manager
Public
Funding
Life
Science
Technologies
Coordinator
ERC
grants
imec
Public
R&D
Policies
&
Programs
wolfgang.eberle@imec.be

19. Workshop
Nanotech
for
Health
in
Flanders
Thursday,
June
20,
2013
(16:00h
-­‐
18:00h)
This
workshop
will
present
the
final
results
of
the
study
“Nanotech
for
Health”
-­‐
conducted
by
ECOOM
and
imec.
Furthermore
the
cluster
organiza>ons
DSP
Valley
and
FlandersBio
will
provide
more
informa>on
on
how
these
results
will
be
used
to
foster
new
R&D
collabora>ons
between
bio-­‐and
nanotechnology
research
centers
and
the
industry
and
other
stakeholders
involved.
http://www.cmi-vzw.be/
Accelerated access to know-how as well as health care products and strategies for
patient and physician.
Better understanding of diseases, their evolution, their treatment and their preventio
The creation of technology platforms that allow for the genesis of new companies w
health care and med-tech.
Smooth transition from academic know-how and understanding to innovation in
process that turns ideas into applications and products.
Get to know the CMI !
CMI is a member of
Leuven.Inc
Visionary
seminar:
‘The
power
of
converging
technologies
for
tomorrow’s
healthcare’
Date:
Thursday
6
June
2013
LocaUon:
imec,
auditorium,
Kapeldreef
75,
3001
Leuven
(Heverlee)
Nanotech
plaVorms
for
healthcare
Peter
Peumans,
Department
Director
Bio-­‐
and
Nanoelectronics
imec
The
New
Age
of
TranslaUonal
Medicine:
Nanotech
meets
Biotech
Magali
Haas,
CSO
One
Mind
for
Research
Trends
towards
smart
specializaUon
Koen
Debackere,
Managing
Director
KU
Leuven
Research
&
Development
Nanotech
for
health
approach
for
Flanders
Marc
Van
Rossum,
Senior
Strategic
Advisor
for
Nanoelectronics
The
Dual
Core
Program
approach:
a
new
concept
of
open
innovaUon
in
the
life
science
community
Johan
Van
Hellepuke,
Senior
Vice
President
Strategic
Development,
imec
Upcoming
events